mCRPC: Practical Considerations for Real World Use of Lutetium Lu 177 Vipivotide Tetraxetan
June 19th 2023Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.
Watch
Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC: VISION and TheraP Trials
June 19th 2023Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.
Watch
Key Data From the BMT CTN 1506/MORPHO Trial of Gilteritinib in FLT3-ITD+ AML
June 15th 2023Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.
Watch